Posts Tagged ‘Drug Delivery’
Panoptes Developing Inhibitor For Local Treatments In Ocular Disease
Panoptes Pharma GmhB is developing PP-001, a dihydroorotate dehydrogenase (DHODH) inhibitor for local treatments in ocular disease, Co-Founder and CEO Franz Obermayr, PhD, told the OIS gathering. Preclinical investigation is focusing on use for intravitreal and oral administration for posterior uveitis, but Panoptes is also researching topical applications for anterior uveitis, dry eye and viral…
Read MorepSivida
Paul Ashton talks about the innovation within pSivida and its early stage work on proteins. pSivida has developed 3 of the 4 sustained delivery systems for the vitreous and retina that have been approved either in the US or the EU Presenter: Paul Ashton Dr. Ashton has over 25 years experience in drug delivery. He…
Read MoreOcular Therapeutix
Amar Sawhney gives us an update on what’s going on in Ocular Therapeutix, showing us an in depth look at their product pipeline and what we can look forward to. Presenter: Amar Sawhney, PhD Amarpreet Sawhney, Ph.D., co-founded Ocular Therapeautix in 2006, has since served as President and CEO and was elected Chairman of the…
Read MoreMimetogen
Presenter: Garth Cumberlidge Garth Cumberlidge has served as the Company’s President, CEO and member of the Board of Directors since September 2005. Dr. Cumberlidge has over 25 years’ experience in the research products, diagnostics and healthcare industries. View Full Profile
Read MoreNeovista – A Challenging Journey
Versant Ventures Managing Director William J. Link PhD talks about the journey of NeoVista through all of its ups and downs. Ultimately Neovista was able to get its CE Mark, but failed to get approved by the FDA due to a spiral of “stacking” risks. Presenter: William J. Link, PhD Bill was Founder, Chairman and…
Read MoreNext Generation Ocular Drug Delivery Platforms
The human eye measures approximately one inch in diameter, but traversing that blink-of-an-eye distance to achieve safe, effective and stable delivery of ophthalmology drugs via minimally or non-invasive medical devices to treat major eye diseases has taken more than 40 years to accomplish. Is the wait for a Holy Grail product in ophthalmology medical technology…
Read More2013 Ophthalmic Market – “Year in Review”
Emmett T. Cunningham Jr. MD PhD MPH, Partner at Clarus Ventures and Summit Chairman, delivers an overview of some ophthalmic highlights from 2013. Sharing key accomplishments from many device and pharma companies, Emmett continues to expand on the present landscape with promising data to show that the ophthalmology market is stable despite the decrease in…
Read MorePanOptica Offers a “Do it Yourself” Treatment for Neovascular AMD
PanOptica – Paul Chaney, President & CEO for PanOptica, expands upon averting intravitreal injections with a topically, self-administered eye drop to treat Neovascular AMD. Striving to decrease the burden of injections and injection related risks, Paul shares the company’s unique discovery that led to their many successes. Presenter: Paul Chaney Paul G. Chaney is Co-Founder,…
Read MoreOphthotech Introduces Their Antigen for WetAMD
David Guyer, CEO, discusses their novel anti-PDGF antigen for Wet AMD. Using FlowVista in combination with standard of care anti-VEGF therapy, David expands on the products successes, which have led to phase three testing and secured financing. Presenter: David Guyer, MD Under Dr. Guyer’s leadership, Ophthotech raised more than $350 million in financing from May…
Read MoreSustained Ophthalmic Therapies Pave the Future for Ocular Therapeutix
Amarpreet Sawhney, President & CEO for Ocular Therapeutix, shares the company’s vision of becoming the leading developer of sustained ophthalmic therapies. Striving to improve patient outcomes, Amarpreet details the company’s proprietary technology that works across the front, back and surface of the eye. Presenter: Amar Sawhney, PhD Amarpreet Sawhney, Ph.D., co-founded Ocular Therapeautix in 2006,…
Read MoreNeurotech Transforms the Delivery of Biologics
Ted Danse, President & CEO for Neurotech, begins by touching upon their ETC technology platform, labeling it as “transformational” in its ability to deliver biologics over multiple years with one simple and minimally invasive procedure. Continuing to detail the key components of their program, Ted expands on the company’s progress thus far. Presenter: Edward (Ted)…
Read MoreALG1001 Leads Allegro’s Progress in Retinal Diseases
Vicken Karageozian, Co-Founder & CTO for Allegro Ophthalmics, shares his company’s story and highlights the progress of their lead molecule, ALG1001, a lead program for several retinal diseases. This program offers a long duration of effect, the option of using combination therapy and treatment for patients who have plateaued or are no longer responding to…
Read More